StockData
Legend Biotech Corp logo

Legend Biotech Corp (LEGN) stock

LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026Score 3/30
$16.11+0.12 (+0.75%)

Close on Nov 17, 2026Market cap $2.98BP/E –Yield –

Legend Biotech r&d expenses

Research and development expenses are spending on new products and technology.

Legend Biotech's R&D Expenses for the twelve months ending Jun 30, 2026 was $396.17M, down 1.0% year over year. For fiscal 2025 it was $414.70M, up 0.3% from the year before. The highest annual figure on record is $414.70M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$414.70M+0.3%
FY2024Dec 31, 2024$413.50M+8.2%
FY2023Dec 31, 2023$382.20M+13.9%
FY2022Dec 31, 2022$335.65M+7.1%
FY2021Dec 31, 2021$313.35M+35.0%
FY2020Dec 31, 2020$232.16M+43.4%
FY2019Dec 31, 2019$161.94M+167.1%
FY2018Dec 31, 2018$60.64M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$96.00M-2.3%
Q1 FY2026Mar 31, 2026$85.70M-15.9%
Q4 FY2025Dec 31, 2025$101.33M-2.9%
Q3 FY2025Sep 30, 2025$113.15M+18.5%
Q2 FY2025Jun 30, 2025$98.30M-12.7%
Q1 FY2025Mar 31, 2025$101.90M+0.9%
Q4 FY2024Dec 31, 2024$104.39M-1.2%
Q3 FY2024Sep 30, 2024$95.52M-0.3%
Q2 FY2024Jun 30, 2024$112.63M+17.6%
Q1 FY2024Mar 31, 2024$100.96M+18.9%
Q4 FY2023Dec 31, 2023$105.67M+30.8%
Q3 FY2023Sep 30, 2023$95.86M-8.3%
Q2 FY2023Jun 30, 2023$95.79M–
Q1 FY2023Mar 31, 2023$84.89M–
Q4 FY2022Dec 31, 2022$80.76M–
Q3 FY2022Sep 30, 2022$104.52M–

More Legend Biotech figures

See a number that looks wrong?